Xact Kapitalforvaltning’s Nektar Therapeutics NKTR Stock Holding History

Xact Kapitalforvaltning’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$509K	Hold	1,902	–	–	0.01%	751
2019 Q4	$616K	Sell	1,902 -537	-22%	-$156K	0.01%	849
2019 Q3	$666K	Buy	2,439 +307	+14%	+$113K	0.01%	759
2019 Q2	$1.14M	Buy	2,132 +31	+1%	+$15.5K	0.02%	532
2019 Q1	$1.06M	Sell	2,101 -105	-5%	-$62.2K	0.02%	565
2018 Q4	$1.09M	Buy	2,206 +207	+10%	+$125K	0.03%	516
2018 Q3	$1.83M	Buy	1,999 +26	+1%	+$22.2K	0.04%	431
2018 Q2	$1.45M	Buy	1,973 +550	+39%	+$634K	0.03%	494
2018 Q1	$2.27M	Buy	1,423 +473	+50%	+$609K	0.05%	371
2017 Q4	$851K	Buy	+950	New	+$562K	0.02%	559

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Xact Kapitalforvaltning's NKTR Position: Q1 2020 in Review

Xact Kapitalforvaltning held its Nektar Therapeutics (NKTR) position steady in Q1 2020 at 1,902 shares worth $509K. The position accounts for 0.01% of the portfolio, ranked #751.

Xact Kapitalforvaltning first reported a position in NKTR in Q4 2017 and has held it in 10 quarters since. The position peaked at $2.27M in Q1 2018. 245 funds tracked by Wall St. Rank hold NKTR as of Q1 2020.

Xact Kapitalforvaltning held 1,902 shares of Nektar Therapeutics worth $509K as of Q1 2020.
Xact Kapitalforvaltning left its Nektar Therapeutics share count unchanged in Q1 2020.
Nektar Therapeutics made up 0.01% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #751 holding.
Xact Kapitalforvaltning first reported a position in Nektar Therapeutics in Q4 2017 and has held it in 10 quarters since.
Xact Kapitalforvaltning's Nektar Therapeutics position peaked at $2.27M in Q1 2018.
245 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.